New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
Implications of Cannabis Legalization for the US Federal Budget
While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.
Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report
In July, MGA CEO Alex Brill submitted a comment letter to the Federal Trade Commission (FTC) expressing concerns about their newly released interim report.
A Balanced Plan for Fiscal Stability and Economic Growth
Our plan seeks to achieve long-term fiscal stability and promote economic growth by aligning federal spending and revenue and pursuing market-based policy reforms.
Implications of Cannabis Legalization for the US Federal Budget
Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.
MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
- New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
- Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
